Aniko Szabo

Jan 1, 2025 | jitc.bmj.com | Binod Dhakal |Parameswaran Hari |Saurabh Chhabra |Aniko Szabo

Immune cell therapies and immune cell engineering Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Aug 11, 2024 | nature.com | Rajshekhar Chakraborty |Aniko Szabo |Carolina Schinke |Binod Dhakal |Ghulam Rehman Mohyuddin |Martin Kaiser | +1 more

To the Editor:Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma [MM], with single-agent response rates from 57–71% [1,2,3,4,5,6].

May 25, 2024 | nature.com | Aniko Szabo

AbstractIt is well-established that most patients with systemic light chain (AL) amyloidosis have multi-organ involvement and are often diagnosed after a lag period of increasing symptoms. We leverage electronic health record (EHR) data from the TriNetX research network to describe the incidence, timing, and co-occurrence of precursor conditions of interests in a cohort of AL amyloidosis patients identified between October 2015-December 2020.

Feb 14, 2024 | nature.com | Meera Mohan |Aniko Szabo |Samer Al Hadidi |Nirav Shah |Frits van Rhee |Mehdi Hamadani | +1 more

AbstractPersistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up.